Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?

10' education - Mar. 18, 2017 - Prof. John Chapman - Paris, France - ACC 2017, Washington DC, USA

PCSK9 Expert Opinions Prof. John Chapman gives his personal views on the results of FOURIER and SPIRE 1&2. Key question is whether in the light of the new data, the LDL-c goal will be maintained or lowered in high-CV risk individuals.

Video navigation menu

What are the take-home messages from FOURIER and SPIRE 1 & 2? 00:57
What are the implications of a favourable safety profile? 01:47
Will we now maintain or lower LDL-c goal in high-risk individuals? 03:00
In summary - a landmark in lipid-lowering therapy 04:29

Educational information

This educational video is part of a series of PCSK9 Expert Opinions that are aimed to provide different perspectives and opinions from international experts in this field and may provide support with the interpretation and translation of new findings towards implications for clinical practice

The educational content reflects the personal opinion of the experts and is recorded as an independent educational service by PACE-CME

Disclosures

Prof. M. John Chapman BSc (Hons), PhD, DSc, FESC - Research Professor, University of Pierre and Marie Curie,- Director Emeritus, INSERM, - Past-President, European Atherosclerosis Society - Pitie-Salpetriere University Hospital - Paris, France

Funding

Funding was provided by an unrestricted educational grant from Amgen

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.